Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EBITDA (2020 - 2025)

Historic EBITDA for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Mirum Pharmaceuticals' EBITDA rose 12052.19% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.8 million, marking a year-over-year increase of 5645.36%. This contributed to the annual value of -$87.6 million for FY2024, which is 1974.09% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its EBITDA stood at $2.6 million for Q3 2025, which was up 12052.19% from -$5.0 million recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year EBITDA high stood at $2.6 million for Q3 2025, and its period low was -$47.6 million during Q1 2021.
  • For the 5-year period, Mirum Pharmaceuticals' EBITDA averaged around -$27.3 million, with its median value being -$27.1 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 11610.84% in 2021, then soared by 12052.19% in 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' EBITDA (Quarter) stood at -$45.6 million in 2021, then grew by 25.04% to -$34.2 million in 2022, then rose by 4.61% to -$32.6 million in 2023, then grew by 25.67% to -$24.2 million in 2024, then soared by 110.75% to $2.6 million in 2025.
  • Its EBITDA was $2.6 million in Q3 2025, compared to -$5.0 million in Q2 2025 and -$15.2 million in Q1 2025.